“I’m particularly skeptical about the use of SNPs to determine whether someone is going to develop a disease or respond or not respond to a drug. The cost of generating SNPs is going to be very low, but the cost of generating phenotypes is going to be very high, and that’s rate limiting.”
David Martin, president and CEO of EOS Biotechnology, speaking at the BIO CEO and Investors Conference in New York City in February
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
